BCAL Diagnostics (ASX:BDX) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BCAL Diagnostics's EBITDA for the six months ended in Dec. 2023 was A$-2.08 Mil. BCAL Diagnostics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, BCAL Diagnostics's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

BCAL Diagnostics EBITDA Margin % Historical Data

The historical data trend for BCAL Diagnostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics EBITDA Margin % Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

EBITDA Margin %

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of BCAL Diagnostics's EBITDA Margin %

For the Diagnostics & Research subindustry, BCAL Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's EBITDA Margin % falls into.

BCAL Diagnostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BCAL Diagnostics's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-7.785	/	0
	=	%

BCAL Diagnostics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.084	/	0
	=	%

BCAL Diagnostics (ASX:BDX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

BCAL Diagnostics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.